Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.82 USD | -0.15% | +8.77% | -0.15% |
May. 28 | Axogen, Inc. Announces the Opening of its Axogen Processing Center | CI |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 706.1 | 718.3 | 389.4 | 422 | 294 | 298.1 | - | - |
Enterprise Value (EV) 1 | 706.1 | 718.3 | 389.4 | 422 | 294 | 298.1 | 298.1 | 298.1 |
P/E ratio | -24.2 x | -29.8 x | -14.4 x | -14.5 x | -13.4 x | -16.5 x | -512 x | 29.7 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 6.62 x | 6.4 x | 3.06 x | 3.05 x | 1.85 x | 1.67 x | 1.48 x | 1.33 x |
EV / Revenue | 6.62 x | 6.4 x | 3.06 x | 3.05 x | 1.85 x | 1.67 x | 1.48 x | 1.33 x |
EV / EBITDA | -23.2 x | -33.3 x | -19.5 x | -45.6 x | -262 x | 20.4 x | 10.5 x | 7.15 x |
EV / FCF | - | - | - | -11.7 x | -15 x | -32.8 x | 21.3 x | 12.1 x |
FCF Yield | - | - | - | -8.56% | -6.66% | -3.05% | 4.7% | 8.25% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 39,469 | 40,126 | 41,563 | 42,287 | 43,044 | 43,705 | - | - |
Reference price 2 | 17.89 | 17.90 | 9.370 | 9.980 | 6.830 | 6.820 | 6.820 | 6.820 |
Announcement Date | 2/24/20 | 2/22/21 | 2/22/22 | 3/14/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 106.7 | 112.3 | 127.4 | 138.6 | 159 | 178.7 | 201 | 224.3 |
EBITDA 1 | -30.47 | -21.6 | -19.94 | -9.259 | -1.12 | 14.62 | 28.4 | 41.7 |
EBIT 1 | -31.41 | -23.18 | -25.42 | -29.71 | -21.46 | -11.24 | 9.238 | 34 |
Operating Margin | -29.43% | -20.64% | -19.96% | -21.44% | -13.5% | -6.29% | 4.6% | 15.16% |
Earnings before Tax (EBT) 1 | -29.14 | -23.79 | -26.98 | -28.95 | -21.72 | -15.53 | 6.738 | 32.5 |
Net income 1 | -29.14 | -23.79 | -26.98 | -28.95 | -21.72 | -18.15 | 5.738 | 26 |
Net margin | -27.3% | -21.18% | -21.19% | -20.89% | -13.66% | -10.16% | 2.85% | 11.59% |
EPS 2 | -0.7400 | -0.6000 | -0.6500 | -0.6900 | -0.5100 | -0.4133 | -0.0133 | 0.2300 |
Free Cash Flow 1 | - | - | - | -36.14 | -19.59 | -9.1 | 14 | 24.6 |
FCF margin | - | - | - | -26.08% | -12.32% | -5.09% | 6.96% | 10.97% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | 49.29% | 58.99% |
FCF Conversion (Net income) | - | - | - | - | - | - | 244.01% | 94.62% |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 2/24/20 | 2/22/21 | 2/22/22 | 3/14/23 | 3/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 31.54 | 31.01 | 34.45 | 36.96 | 36.16 | 36.66 | 38.16 | 41.27 | 42.92 | 41.38 | 43.36 | 46.35 | 47.67 | 47 | 48.78 |
EBITDA 1 | -3.669 | -7.357 | -1.587 | 0.368 | -0.683 | -3.79 | -0.246 | 2.354 | 0.567 | 1.002 | 3.352 | 4.73 | 5.542 | 4.304 | 5.582 |
EBIT 1 | -5.353 | -11.32 | -7.924 | -4.855 | -5.608 | -7.341 | -6.902 | -4.025 | -3.194 | -4.56 | -3.377 | -2 | -1.338 | -1.23 | 0.049 |
Operating Margin | -16.97% | -36.51% | -23% | -13.14% | -15.51% | -20.02% | -18.09% | -9.75% | -7.44% | -11.02% | -7.79% | -4.32% | -2.81% | -2.62% | 0.1% |
Earnings before Tax (EBT) 1 | -5.286 | -11.48 | -7.74 | -4.318 | -5.415 | -7.074 | -6.66 | -4.089 | -3.893 | -6.635 | -4.177 | -2.7 | -2.038 | -1.73 | -0.451 |
Net income 1 | -5.286 | -11.48 | -7.74 | -4.318 | -5.415 | -7.074 | -6.66 | -4.089 | -3.893 | -6.635 | -4.618 | -3.6 | -3.325 | -1.73 | -0.451 |
Net margin | -16.76% | -37.01% | -22.46% | -11.68% | -14.97% | -19.29% | -17.46% | -9.91% | -9.07% | -16.04% | -10.65% | -7.77% | -6.98% | -3.68% | -0.92% |
EPS 2 | -0.1300 | -0.2700 | -0.1800 | -0.1000 | -0.1300 | -0.1700 | -0.1600 | -0.1000 | -0.0900 | -0.1500 | -0.1033 | -0.0800 | -0.0733 | -0.0400 | -0.0100 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/22/22 | 5/4/22 | 8/3/22 | 11/8/22 | 3/14/23 | 5/9/23 | 8/7/23 | 11/7/23 | 3/5/24 | 5/2/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | - | -36.1 | -19.6 | -9.1 | 14 | 24.6 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | 21.9 | 27.8 | 20.1 | 13.9 | 4.7 | 5 | 5 |
Capex / Sales | - | 19.51% | 21.84% | 14.49% | 8.72% | 2.63% | 2.49% | 2.23% |
Announcement Date | 2/24/20 | 2/22/21 | 2/22/22 | 3/14/23 | 3/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.15% | 299M | |
+7.31% | 217B | |
+12.99% | 190B | |
+19.71% | 143B | |
+30.60% | 111B | |
+0.65% | 64.59B | |
+15.23% | 52.36B | |
+2.06% | 48.45B | |
-5.49% | 38.03B | |
-0.22% | 35.6B |
- Stock Market
- Equities
- AXGN Stock
- Financials AxoGen, Inc.